Drug Discovery
By
Pfizer Secures Exclusive Global Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
Key Highlights A Bold Bet on BispecificsIn a significant expansion of its oncology pipeline, Pfizer has obtained exclusive…
Can AstraZeneca’s Imfinzi Redefine Gastric Cancer Treatment With FDA Priority Review Backing?
Key Highlights A New Chapter for Immunotherapy in Early-Stage GI CancersAstraZeneca’s Imfinzi is poised to become the first…
Could GSK and Hengrui’s $12B Alliance Set a New Standard in China-Originated Drug Collaborations?
Key Highlights GSK Bets Big on Hengrui: A $12B Strategic Play Anchored in Respiratory InnovationIn a high-stakes bet…
Can IGC Pharma’s New AI Models Change Alzheimer’s Diagnosis and Drug Discovery for Millions?
New tools unveiled at AAIC 2025 aim to detect Alzheimer’s earlier and faster, even in low-resource settings Key…
Could Roche and Alnylam’s Phase III Trial of Zilebesiran Redefine Hypertension Care for 1.2 Billion Patients Worldwide?
Key Highlights Phase II Data Paves the WayThe KARDIA clinical program—spanning three Phase II trials—has provided the foundation…
Can Cambridge and A*STAR’s New AI Digital Twin Platform Transform $50Bn Pharma Manufacturing Efficiency Landscape?
Key Takeaways AI-Driven Digital Twin for PharmaThe newly launched platform integrates AI with real-time plant data to create…
